Business Description
Aurinia Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
Compare
Compare
Traded in other countries / regions
AUP.CanadaIKAP.Germany0UJF.UKAUPH.USA IPO Date
2009-10-21Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 48.14 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.41 | |||||
| Beneish M-Score | -1.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 580.2 | |||||
| 3-Year EBITDA Growth Rate | 7.4 | |||||
| 3-Year EPS without NRI Growth Rate | 7.2 | |||||
| 3-Year FCF Growth Rate | 6.4 | |||||
| 3-Year Book Growth Rate | 2.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 19.55 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.33 | |||||
| 9-Day RSI | 59.55 | |||||
| 14-Day RSI | 58.75 | |||||
| 6-1 Month Momentum % | 12.19 | |||||
| 12-1 Month Momentum % | -29.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.6 | |||||
| Quick Ratio | 9.06 | |||||
| Cash Ratio | 8.45 | |||||
| Days Inventory | 1566.29 | |||||
| Days Sales Outstanding | 59.5 | |||||
| Days Payable | 219.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.4 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.77 | |||||
| Operating Margin % | -83.17 | |||||
| Net Margin % | -80.71 | |||||
| ROE % | -24.81 | |||||
| ROA % | -21.71 | |||||
| ROIC % | -210.6 | |||||
| ROC (Joel Greenblatt) % | -353.75 | |||||
| ROCE % | -24.29 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.78 | |||||
| PB Ratio | 3.25 | |||||
| Price-to-Tangible-Book | 3.3 | |||||
| EV-to-EBIT | -8.76 | |||||
| EV-to-EBITDA | -8.98 | |||||
| EV-to-Revenue | 7.29 | |||||
| EV-to-Forward-Revenue | 7.07 | |||||
| EV-to-FCF | -12.24 | |||||
| Price-to-Net-Current-Asset-Value | 3.49 | |||||
| Price-to-Net-Cash | 4.06 | |||||
| Earnings Yield (Greenblatt) % | -11.42 |
How Aurinia Pharmaceuticals Inc (AUPH) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AUPH
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Details
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 134.03 | ||
| EPS (TTM) ($) | -0.76 | ||
| Beta | 1.18 | ||
| Volatility % | 126.1 | ||
| 14-Day RSI | 58.75 | ||
| 14-Day ATR ($) | 0.585209 | ||
| 20-Day SMA ($) | 8.9095 | ||
| 12-1 Month Momentum % | -29.52 | ||
| 52-Week Range ($) | 4.07 - 13.415 | ||
| Shares Outstanding (Mil) | 142.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aurinia Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aurinia Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aurinia Pharmaceuticals Inc Frequently Asked Questions
What is Aurinia Pharmaceuticals Inc(AUPH)'s stock price today?
The current price of AUPH is $9.27. The 52 week high of AUPH is $13.42 and 52 week low is $4.07.
When is next earnings date of Aurinia Pharmaceuticals Inc(AUPH)?
The next earnings date of Aurinia Pharmaceuticals Inc(AUPH) is 2023-05-10 Est..
Does Aurinia Pharmaceuticals Inc(AUPH) pay dividends? If so, how much?
Aurinia Pharmaceuticals Inc(AUPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
